DVAX
Company Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Track Record
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 277.25M | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327,000 | 11.04M | 4.05M | 11.03M | 11.25M |
| Net Income | 27.31M | (6.39M) | 293.16M | 76.71M | (75.24M) | (152.60M) | (158.90M) | (95.15M) | (112.44M) | (106.79M) | (90.72M) | (66.72M) |
| EPS | 0.21 | -0.05 | 2.32 | 0.62 | -0.75 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 |
| Free Cash Flow | 60.16M | 96.46M | 55.58M | 326.05M | (103.32M) | (150.65M) | (146.49M) | (78.19M) | (114.81M) | (99.53M) | N/A | N/A |
| FCF / Share | 0.46 | 0.75 | 0.44 | 2.80 | -1.03 | -2.09 | -2.35 | -1.49 | -2.98 | -3.03 | N/A | N/A |
| Operating CF | 66.51M | 100.56M | 62.72M | 335.53M | (92.25M) | (121.25M) | (131.30M) | (77.52M) | (107.05M) | (92.56M) | N/A | N/A |
| Total Assets | 986.26M | 997.10M | 985.85M | 1.04B | 353.27M | 279.07M | 210.88M | 218.78M | 109.68M | 216.63M | N/A | N/A |
| Total Debt | 254.42M | 256.91M | 258.01M | 257.38M | 217.85M | 216.45M | 100.87M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 95.88M | 150.28M | 202.00M | 436.19M | 32.07M | 39.88M | 49.35M | 26.58M | 24.29M | 44.81M | N/A | N/A |
| Book Value | 596.80M | 622.07M | 581.01M | 222.37M | 58.69M | 8.29M | 63.06M | 199.55M | 89.20M | 187.08M | N/A | N/A |
| Return on Equity | 0.05 | -0.01 | 0.50 | 0.34 | -1.28 | -18.41 | -2.52 | -0.48 | -1.26 | -0.57 | N/A | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.88M | 95.44M | 68.16M | 72.03M | 80.63M | 73.80M | 50.79M | 55.60M | 69.51M | 60.25M | 46.92M | 184.49M |
| Net Income | 26.93M | 18.72M | (96.10M) | 7.05M | 17.59M | 11.39M | (8.72M) | 219,000 | 14.29M | 3.43M | (24.33M) | 67.73M |
| EPS | 0.23 | 0.16 | -0.77 | 0.06 | 0.13 | 0.09 | -0.07 | 0.00 | 0.11 | 0.03 | -0.19 | 0.53 |
| Free Cash Flow | 32.59M | 21.98M | (23.57M) | 49.53M | 18.12M | 9.93M | (17.43M) | 12.04M | 30.78M | 27.30M | 26.34M | 33.36M |
| FCF / Share | 0.28 | 0.18 | -0.19 | 0.39 | 0.14 | 0.08 | -0.13 | 0.09 | 0.24 | 0.21 | 0.21 | 0.26 |
| Operating CF | 33.83M | 23.43M | (19.64M) | 53.01M | 19.47M | 10.71M | (16.68M) | 13.77M | 31.13M | 28.05M | 27.62M | 34.95M |
| Total Assets | 946.51M | 918.45M | 945.93M | 986.26M | 1.06B | 1.02B | 986.57M | 997.10M | 972.93M | 936.43M | 969.92M | 985.85M |
| Total Debt | 285.02M | 285.50M | 286.03M | 254.42M | 250.17M | 255.28M | 256.10M | 256.91M | 257.49M | 257.83M | 257.82M | 258.01M |
| Cash & Equiv | 160.25M | 99.10M | 51.72M | 95.88M | 119.33M | 112.50M | 132.03M | 150.28M | 154.51M | 226.82M | 174.35M | 202.00M |
| Book Value | 534.14M | 494.16M | 530.94M | 596.80M | 681.43M | 642.85M | 618.48M | 622.07M | 604.92M | 577.21M | 563.73M | 581.01M |
| Return on Equity | 0.05 | 0.04 | -0.18 | 0.01 | 0.03 | 0.02 | -0.01 | 0.00 | 0.02 | 0.01 | -0.04 | 0.12 |
